{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-051374","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2024-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.314782+00:00","generated_at":"2026-05-29T02:50:35.823305+00:00","sec_items":["4.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ChromaDex appoints Crowe LLP as new independent auditor effective December 13, 2024","bullets":["Audit Committee approved Crowe LLP as independent auditor for fiscal year ending Dec 31, 2024, effective Dec 13, 2024.","No disagreements with prior auditor during fiscal years 2023 and 2022 and subsequent interim period.","No consultations with Crowe regarding application of accounting principles or audit opinion prior to engagement.","Change follows competitive request-for-proposal process conducted by Audit Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-051374","json":"https://secwatch.observer/filing/0001628280-24-051374.json","markdown":"https://secwatch.observer/filing/0001628280-24-051374.md","text":"https://secwatch.observer/filing/0001628280-24-051374.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024051374/0001628280-24-051374-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024051374/cdxc-20241213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:50:35.823305+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}